Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2012.591
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Relaxin Enhances S100A4 and Promotes Growth of Human Thyroid Carcinoma Cell Xenografts

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2010English

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After Nephrectomy

New England Journal of Medicine
Medicine
2016English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

The Function of COX-2 in Human Ovarian Carcinoma

American Journal of Pathology
Forensic MedicinePathology
2003English

VEGF-C, VEGFR-3, and COX-2 Enhances Growth and Metastasis of Human Cervical Carcinoma Cell Lines in Vitro

Oncology Reports
MedicineCancer ResearchOncology
2007English

A Rare Case of Sunitinib-Induced Rhabdomyolysis in Renal Cell Carcinoma

Case Reports in Oncological Medicine
Oncology
2018English

Significance of Cyclooxygenase‑2, Prostaglandin E2 and CD133 Levels in Sunitinib‑resistant Renal Cell Carcinoma

Oncology Letters
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy